SCHEMBL4112264

SCHEMBL4112264

CCOc1ccc(NC(=O)Nc2ccc(C(C)C)cc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.74
MEN1 O00255 5/20 0.74
KMT2A Q03164 5/20 0.74
RAB9A P51151 5/20 0.69
ALDH1A1 P00352 3/20 0.67
POLB P06746 3/20 0.61
LMNA P02545 2/20 0.61
TDP1 Q9NUW8 2/20 0.61
CYP1A2 P05177 1/20 0.61
CA12 O43570 1/20 0.61
CA1 P00915 1/20 0.61
CA2 P00918 1/20 0.61
CA9 Q16790 1/20 0.61
GAA P10253 2/20 0.61
EPHX1 P07099 1/20 0.59
MAPK1 P28482 1/20 0.59
EPHX2 P34913 1/20 0.59
NPC1 O15118 3/20 0.58
PKM P14618 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10576308 0.88 MAPT (0.86) MAPTMEN1KMT2ARAB9AALDH1A1
SCHEMBL4105911 0.88 RAB9A (0.66) MAPTMEN1KMT2ARAB9AALDH1A1
SCHEMBL4123365 0.86 KMT2A (0.61) MAPTMEN1KMT2ARAB9AALDH1A1
SCHEMBL4117849 0.84 MAPT (0.73) MAPTMEN1KMT2ARAB9AALDH1A1
SCHEMBL19707622 0.83 RAB9A (0.76) MAPTMEN1KMT2ARAB9ACA12
SCHEMBL22104836 0.83 ALDH1A1 (0.78) MAPTMEN1KMT2ARAB9AALDH1A1
SCHEMBL4104467 0.82 MAPT (0.76) MAPTMEN1KMT2ARAB9AALDH1A1
SCHEMBL4118269 0.82 RAB9A (1.00) MAPTMEN1KMT2ARAB9AALDH1A1
SCHEMBL683602 0.81 NQO1 (0.67) MAPTMEN1KMT2ARAB9APOLB
SCHEMBL4113061 0.81 MAPT (0.73) MAPTMEN1KMT2ARAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 MAPT 1654/4885MEN1 3273/4885KMT2A 2807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.